Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 41, 3711-3717, September 1, 1981]
© 1981 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirschner, M. A.
Right arrow Articles by Schneider, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirschner, M. A.
Right arrow Articles by Schneider, G.

Obesity, Hormones, and Cancer1

Marvin A. Kirschner2, Norman Ertel and George Schneider

Newark Beth Israel Medical Center, Newark, New Jersey 07112, New Jersey Medical School, Newark, New Jersey 07103, and the Veteran's Administration Hospital, East Orange, New Jersey 07019

Obesity is a physiological state associated with alterations in hormone production and metabolism. These hormonal changes may bear on the increased risk for selected neoplastic disorders.

Obesity is associated with increased estrone production in young and older women as well as in men. The source of this increased estrogen appears to be extragonadal metabolism of the prehormone androstenedione, which increases 3- to 4-fold in proportion to the obesity. In severe obesity, androstenedione production itself may be increased, providing extra prehormone for conversion to estrogens. In addition, obesity appears to shift peripheral metabolism of estradiol, resulting in decreased excretion of catechol estrogens which in turn may influence target organ stimulation.

Testosterone production is unchanged in obesity; however, there are decreased levels of sex hormone-binding ß-globulin leading to increased clearance rates and spuriously low levels of circulating testosterone in both obese men and obese women. Alterations in sex hormone-binding ß-globulin may further lead to changes in "free" estradiol, which may play a role in target organ stimulation.

Other changes noted in obesity include: (a) increased excretion of corticoid metabolites; (b) increased secretion of insulin but decreased insulin effectiveness; (c) blunted growth hormone responses to various challenges; and (d) possibly blunted prolactin responsiveness. There are no reasons at present to suspect that these changes influence cancer risk.

With weight loss, sex hormone-binding ß-globulin changes are restored toward normal as are the elevated plasma estrogens and decreased testosterone levels. Because weight loss and dieting per se are associated with many physiological changes, hormonal measurements during these times are difficult to interpret. Few studies to date have been performed in formerly obese patients stabilized at their new weight.

1 Presented at the Workshop on Fat and Cancer, December 10 to 12, 1979, Bethesda, Md.

2 To whom requests for reprints should be addressed, at Newark Beth Israel Medical Center, 201 Lyons Ave., Newark, N. J. 07112.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1981 by the American Association for Cancer Research.